Subject anti-HCV antibody detection assays employing NS3 capture peptides

US10088483B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10088483-B2
Application numberUS-201514925778-A
CountryUS
Kind codeB2
Filing dateOct 28, 2015
Priority dateOct 29, 2014
Publication dateOct 2, 2018
Grant dateOct 2, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure provides methods, kits, and compositions for detecting subject anti-HCV antibodies in a sample using NS3 capture peptides. In certain embodiments, at least two NS3 helicase (NS3h) capture peptides and at least two conjugate peptides (e.g., NS3h conjugate peptides) are employed together, which allows for a broad dynamic range of subject antibody detection in a one-step type assay. In other embodiments, methods are provided of detecting NS3-specific subject antibodies without the use of a reducing agent. In some embodiments, NS3-specific subject antibodies are detected with a ‘double shot’ of NS3 conjugate peptide (e.g., conjugate peptide added to a sample both before and after washing).

First claim

Opening claim text (preview).

We claim: 1. A method of detecting hepatitis C virus (HCV) infection in a subject comprising: a) contacting an initial biological sample with first and second NS3h capture peptides and first and second detectably labeled conjugate peptides to generate a mixed biological sample that comprises said initial biological sample, said first and second NS3h capture peptides, and said first and second conjugate peptides, wherein said first NS3h capture peptide has at least 90% sequence identity with an HCV NS3 helicase Domain 1, and is no more than 200 amino acids in length, wherein said second NS3h capture peptide has at least 95% sequence identity with a full-length NS3 helicase having Domains 1, 2, and 3, and wherein said initial biological sample is suspected of containing subject antibodies, and wherein said subject antibodies are not in purified form in said biological sample, b) incubating said mixed biological sample under conditions such that: said first NS3h capture peptide specifically binds at least one of said subject antibodies to form a first capture complex and said first conjugate peptide binds said subject antibody in said first capture complex to form a first detectable complex, and said second NS3h capture peptide specifically binds at least one of said subject antibodies to form a second capture complex and said second conjugate peptide binds said subject antibody in said second capture complex to form a second detectable complex; c) washing said mixed biological sample to generate a washed sample; and d) detecting the presence of said first and/or second detectable complexes, thereby detecting the presence of past or present HCV infection in said subject, wherein the presence of both said first and second NS3h capture peptides in said mixed biological sample extends the dynamic range for qualitatively detecting said subject antibodies compared to only using said first or second NS3h capture peptide. 2. The method of claim 1 , wherein said amino acid sequence of said second NS3h capture peptide is at least two times longer than said first NS3h capture peptide. 3. The method of claim 1 , wherein said first and second conjugate peptides are specific for an NS3h epitope. 4. The method of claim 1 , wherein said second NS3h capture peptide comprises a full-length NS3 helicase sequence having Domains 1, 2, and 3. 5. The method of claim 1 , wherein said amino acid sequence of said second NS3h capture peptide has at least 99% sequence identity with said full-length HCV helicase. 6. The method of claim 1 , wherein said amino acid sequence of said second NS3h capture peptide comprises a full-length NS3 helicase sequence having Domains 1, 2, and 3.

Assignees

Inventors

Classifications

  • Hepatitis C; Hepatitis NANB · CPC title

  • non-A, non-B hepatitis · CPC title

  • Detection of antibodies in sample from host which are directed against antigens from microorganisms · CPC title

  • Hydrolases (3) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10088483B2 cover?
The present disclosure provides methods, kits, and compositions for detecting subject anti-HCV antibodies in a sample using NS3 capture peptides. In certain embodiments, at least two NS3 helicase (NS3h) capture peptides and at least two conjugate peptides (e.g., NS3h conjugate peptides) are employed together, which allows for a broad dynamic range of subject antibody detection in a one-step typ…
Who is the assignee on this patent?
Abbott Lab
What technology area does this patent fall under?
Primary CPC classification G01N33/5767. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).